The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome

Endocrine Journal

Volumn 58, Issue 4, 2011, Pages 237-246

  Koiou, Ekaterini ^a   Tziomalos, Konstantinos ^a   Dinas, Konstantinos ^a   Katsikis, Ilias ^a   Kalaitzakis, Emmanuil ^a   Delkos, Dimitrios ^a   Kandaraki, Eleni A ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Metformin; Obesity; Orlistat; Polycystic ovary syndrome; Vaspin

Indexed keywords

METFORMIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; VASPIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; BODY MASS INDEX; CYCLOBUTANES; DIET, REDUCING; FEMALE; HUMANS; LACTONES; METFORMIN; OVERWEIGHT; POLYCYSTIC OVARY SYNDROME; SERPINS; WEIGHT LOSS;

EID: 79955779344     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-330     Document Type: Article

References (39)

1. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 18: 774-800.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI (1999) A Survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006-4011.
3. Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358: 47-54.
4. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB (1985) Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61: 946-951.
5. Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D (2009) The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome. Obes Rev 10: 431-441.
6. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS (1995) Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10: 2107-2111.
7. Legro RS (2000) The genetics of obesity. Lessons for polycystic ovary syndrome. Ann NY Acad Sci 900: 193-202.
8. Chang RJ, Nakamura RM, Judd HL, Kaplan SA (1983) Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57: 356-359.
9. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A (1987) Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperisulinemia. J Clin Endocrinol Metab 65: 499-507.
10. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165-1174.
11. Trujillo ME, Scherer PE (2006) Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27: 762-778.
12. Vona-Davis L, Howard-McNatt M, Rose DP (2007) Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer (Complication of Obesity). Obes Rev 8: 395-408.
13. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556.
14. Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21: 697-738.
15. Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P (2002) A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 26: 193-199.
16. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci 102: 10610-10615.
17. Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Blüher M (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339: 430-436.
18. Youn BS, Klöting N, Kratzsch J, Park JW, Lee N, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Blüher M (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57: 372-377.
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47.
20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19-25.
21. Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G (2008) Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 89: 899-906.
22. Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D (2008) Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obesity 32: 692-699.
23. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D (2009) Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 296: E238-243.
24. Morley JE, Patrick P, Perry HM (2002) Evaluation of assays available to measure free testosterone. Metabolism 51: 554-559.
25. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 12-19.
26. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410.
27. Carrell R, Travis J (1985) α1-Antitrypsin and the serpins: variation and countervariation. Trends Bioch Sci 10: 20-24.
28. Gettins PG (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804.
29. Baxter EW, Cummings WJ, Fournier REK (2005) Formation of a large, complex domain of histone hyperacetylation at human 14q32.1 requires the serpin locus control region. Nucleic Acids Res 33: 3313-3322.
30. Hida K, Wada J, Zhang H, Hiragushi K, Tsuchiyama Y, Shikata K, Makino H (2000) Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res 41: 1615-1622.
31. Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS (2008) Metformin decreases the adipokine Vaspin in overweight women with polycystic ovary concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 57: 1501-1507.
32. Escobar-Morreale HF, Luque-Ramirez M, San-Millan JL (2009) Serum visceral adipose tissue-derived serine protease inhibitor concentrations in human obesity and polycystic ovary syndrome. Diabetes Care 32: e6.
33. Cakal E, Ustun Y, Engin-Ustun Y, Ozkaya M, Kilinc M (2010) Serum vaspin and C-reactive protein levels in women with polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol epub ahead of print.
34. Johnson AB, Webster JM, Sum CF, Heseltine L, Argyraki M, Cooper BG, Taylor R (1993) The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 42: 1217-1222.
35. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43: 920-928.
36. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-873.
37. Nestler JE, Jakubowicz DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: 4075-4079.
38. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72: 83-89.
39. Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358: 47-54.